Lupin plunges on getting warning letter from USFDA for Mandideep (Unit-1) facility

19 Sep 2019 Evaluate

Lupin is currently trading at Rs. 739.00, down by 20.50 points or 2.70% from its previous closing of Rs. 759.50 on the BSE.

The scrip opened at Rs. 762.00 and has touched a high and low of Rs. 762.00 and Rs. 733.85 respectively. So far 106692 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 941.10 on 19-Sep-2018 and a 52 week low of Rs. 697.30 on 19-Jun-2019.

Last one week high and low of the scrip stood at Rs. 780.00 and Rs. 733.85 respectively. The current market cap of the company is Rs. 33762.98 crore.

The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.66% and 14.38% respectively.

Lupin has received warning letter from the United States Food and Drug Administration (USFDA) for its Mandideep (Unit-1) facility. This is subsequent to an earlier intimation received from the USFDA in March 2019 wherein the agency had classified its inspection conducted at the said facility in December 2018 as Official Action Indicated (OAI).

There are no DMF and ANDA applications pending review or approval from the Mandideep (Unit-1) facility and the company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2114.10 33.75 (1.62%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×